Briacell Therapeutics Corp (BCTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Briacell Therapeutics Corp (BCTX) has a cash flow conversion efficiency ratio of -0.302x as of April 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.08 Million) by net assets ($23.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BCTX company net worth for the company's overall valuation and market capitalisation.
Briacell Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Briacell Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Briacell Therapeutics Corp ranked by their cash flow conversion efficiency. Explore cash flow quality index of Briacell Therapeutics Corp to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Next Science Ltd
AU:NXS
|
2.498x |
|
Tate & Lyle PLC
LSE:TATE
|
0.074x |
|
SBF AG
F:CY1K
|
N/A |
|
Apollomics Inc. Class A Ordinary Shares
NASDAQ:APLM
|
4.001x |
|
Shanghai Lingyun Industries Development Co Ltd
SHG:900957
|
-0.002x |
|
Kalamazoo Resources Ltd
AU:KZR
|
-0.028x |
|
Wattana Karnpaet Public Company Limited
BK:NEW
|
0.042x |
|
Taiming Assurance Broker Co Ltd
TWO:5878
|
0.011x |
Annual Cash Flow Conversion Efficiency for Briacell Therapeutics Corp (2006–2025)
The table below shows the annual cash flow conversion efficiency of Briacell Therapeutics Corp from 2006 to 2025. View BCTX share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | $23.83 Million | $-39.07 Million | -1.639x | -118.54% |
| 2024-07-31 | $-3.73 Million | $-32.97 Million | 8.845x | +39.91% |
| 2023-07-31 | $-5.04 Million | $-31.89 Million | 6.322x | +627.54% |
| 2022-07-31 | $13.25 Million | $-15.87 Million | -1.198x | -319.15% |
| 2021-07-31 | $34.58 Million | $-9.89 Million | -0.286x | -166.16% |
| 2020-07-31 | $-3.60 Million | $-1.55 Million | 0.432x | -94.19% |
| 2019-07-31 | $-688.66K | $-5.12 Million | 7.434x | +241.81% |
| 2018-07-31 | $945.02K | $-4.95 Million | -5.242x | -105.75% |
| 2017-07-31 | $750.23K | $-1.91 Million | -2.548x | -27.07% |
| 2016-07-31 | $787.11K | $-1.58 Million | -2.005x | -95.86% |
| 2015-07-31 | $1.16 Million | $-1.19 Million | -1.024x | -100.29% |
| 2014-07-31 | $-1.13K | $-397.42K | 352.638x | +862188.34% |
| 2013-07-31 | $9.33 Million | $-381.80K | -0.041x | -7.25% |
| 2012-07-31 | $10.03 Million | $-382.74K | -0.038x | +32.46% |
| 2011-07-31 | $11.63 Million | $-656.68K | -0.056x | +74.43% |
| 2010-07-31 | $1.44 Million | $-318.63K | -0.221x | -42.45% |
| 2009-07-31 | $974.50K | $-151.05K | -0.155x | +36.89% |
| 2008-07-31 | $365.17K | $-89.68K | -0.246x | -25.01% |
| 2007-07-31 | $446.71K | $-87.76K | -0.196x | -1492.27% |
| 2006-07-31 | $79.82K | $1.13K | 0.014x | -- |
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more